ASMB ASSEMBLY BIOSCIENCES, INC.

Nasdaq assemblybio.com


$ 29.46 $ 0.37 (1.27 %)    

Friday, 17-Oct-2025 15:59:56 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 29.45
$ 28.92
$ 28.75 x 100
$ 30.20 x 50
$ 28.82 - $ 30.20
$ 7.75 - $ 30.20
291,349
na
225.95M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-04-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-05-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-07-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-08-2017 03-31-2017 10-Q
35 03-02-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 assembly-biosciences-files-prospectus-relates-to-offering-resale-from-time-to-time-of-up-to-698m-shares-by-selling-stockholder

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-assembly-biosciences-maintains-50-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $...

 4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

 jmp-securities-initiates-coverage-on-assembly-biosciences-with-market-outperform-rating-announces-price-target-of-38

JMP Securities analyst Roy Buchanan initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Market Outperform rating...

 guggenheim-maintains-buy-on-assembly-biosciences-raises-price-target-to-39

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $31 ...

 hc-wainwright--co-assumes-assembly-biosciences-at-buy-announces-price-target-of-50

HC Wainwright & Co. analyst Patrick Trucchio assumes Assembly Biosciences (NASDAQ:ASMB) with a Buy rating and announces ...

 assembly-biosciences-announced-interim-data-from-several-cohorts-from-the-ongoing-phase-1a-trial-of-abi-6250-for-hepatitis-delta-virus

Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-62...

 reported-saturday-assembly-biosciences-presents-phase-1a-and-preclinical-data-for-abi-5366-and-abi-1179-herpes-candidates-at-sti--hiv-2025-and-international-herpesvirus-workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex vir...

 assembly-biosciences-announces-topline-results-from-its-phase-1b-clinical-trial-of-next-generation-investigational-capsid-assembly-modulator-abi-4334-in-chronic-hepatitis-b

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be obs...

 syndeio-biosciences-launches-to-pioneer-precision-neurotherapeutics-focused-on-repairing-and-enhancing-synaptic-function-in-central-nervous-system-diseases

Clinical portfolio, informed by deep and novel synapse biology and pharmacology insights, aims to strengthen neural connections...

 assembly-biosciences-q1-eps-117-beats-160-estimate-sales-942m-beat-763m-estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of ...

 assembly-biosciences-releases-new-preclinical-date-for-oral-hepatitis-d-virus-entry-inhibitor-abi-6250-and-next-generation-hepatitis-b-virus-capsid-assembly-modulator-abi-4334-at-the-easl-congress-2025-in-amsterdam

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 –– Sec...

 assembly-biosciences-unveils-data-on-long-acting-hsv-candidate-abi-5366-and-us-genital-herpes-trends-at-2025-escmid-congress

– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase i...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION